Drug Treatment for Pathological Gambling

This study has been completed.

First Received: February 28, 2003 Last Updated: February 15, 2008 History of Changes

Sponsor:	National Institute of Mental Health (NIMH)
Information provided by:	National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:	NCT00055393

Purpose

This study will determine whether the drug bupropion is an effective treatment for Pathological Gambling.

Condition	Intervention
Gambling	Drug: Bupropion

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Bupropion Versus Placebo in the Treatment of Pathological Gambling

Resource links provided by NLM:

MedlinePlus related topics: Compulsive Gambling

Drug Information available for: Bupropion hydrochloride Bupropion

U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment:	80
Study Start Date:	July 2002
Study Completion Date:	April 2006
Estimated Primary Completion Date:	May 2005 (Final data collection date for primary outcome measure)

Detailed Description:

As gambling opportunities proliferate, PG has become a major health concern. Despite its importance, few treatment options with proven efficacy exist. This study will attempt to identify an effective treatment for PG.

Participants are randomly assigned to receive either bupropion or placebo for 12 weeks. Participants are assessed at baseline and at Weeks 2, 3, 4, 5, 6, 8, 10, and 12. Self administered questionnaires and interviews are used to assess participants. Follow-up assessments are made 1, 3, and 6 months after study completion.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

PG for at least 1 year

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00055393

Locations

United States, Iowa
Roy J. and Lucille A. Carver College of Medicine, University of Iowa
Iowa City, Iowa, United States, 52242

Sponsors and Collaborators

National Institute of Mental Health (NIMH)

More Information

No publications provided

Study ID Numbers:	R21 MH63289, DSIR AT-AS
Study First Received:	February 28, 2003
Last Updated:	February 15, 2008
ClinicalTrials.gov Identifier:	NCT00055393 History of Changes
Health Authority:	United States: Federal Government

Additional relevant MeSH terms:

Dopamine Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Psychotropic Drugs
Pharmacologic Actions
Impulse Control Disorders

Gambling
Mental Disorders
Therapeutic Uses
Bupropion
Dopamine Agents
Antidepressive Agents, Second-Generation
Central Nervous System Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on November 22, 2009